[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546369":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":19,"responsibleParty":37,"collaborators":10,"id":41,"slug":10,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observation",null,"Active surveillance",[13],"Procedure: Active surveillance",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","Conduct thoracic computed tomography scans every 12 months. If progression occurs, the treamtent approach would involve surgery.",[9],[20],{"facility":21,"status":10,"city":22,"state":10,"zip":10,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Fudan University Shanghai Cancer Center","Shanghai","China",{"type":25,"coordinates":26},"Point",[27,28],121.45806,31.22222,{"lat":28,"lon":27},[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Haoxuan Wu","CONTACT","86-64175590","63189","haoxuanwu@hotmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Haiquan Chen","Director in the Department of Thoracic Surgery, FUSCC","100546369",false,"NCT06394037","Active Surveillance for Limited GGNs","Active Surveillance for Patients with Limited Ground-glass Nodules in China: a Prospective Multi-center Single-arm Trial (ECTOP-1028)","Patients eligible for enrollment in the study are required to meet all the following criteria.\n\n1. Demonstrates the following on thin-section computed tomography (TSCT) scan:\n\n   1. Presence of one or two GGNs (bilateral lesions are permitted).\n   2. All lesions have remained stable without regression or enlargement for at least 3 months.\n   3. The dominant lesion (the lesion with the largest maximum tumor diameter) has a maximum tumor diameter ≥0.6cm and ≤2cm.\n   4. CTR ≤0.25 in lesions.\n   5. No lymph node with a diameter \\>1cm in the mediastinal view.\n   6. Not adjacent to the pleura in dominant lesion and no sign of pleural retraction in any lesions.\n2. Has not previously undergo any anti-tumor drug or radiation therapy for the lung lesions.\n3. Aged 18-75 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n5. Written informed consent.\n\nPatients will be excluded if they meet any of the following criteria.\n\n1. History of any prior malignancies within the past 5 years.\n2. History of lung surgery.\n3. History of interstitial pneumonia, pulmonary fibrosis or other severe pulmonary diseases.\n4. Presence of severe or uncontrolled diseases that may possibly reduce the 10-year life expectancy.","ALL","18 Years","75 Years",{"count":51,"type":52},387,"ESTIMATED","10 Years","OBSERVATIONAL","This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) . The primary objective of the study is to assess the 5-year overall survival of patients with one or two ground-glass opacities by employing an active surveillance approach rather than immediate surgical resection.",[57,58],"Lung Ground-glass Opacities","Active Surveillance","NOT_YET_RECRUITING","2025-01-29",{"date":62,"type":63},"2025-01-31","ACTUAL",{"date":65,"type":52},"2025-05-01",{"date":67,"type":52},"2038-05-01",{"name":5,"class":6},1]